ArticleJAMA network open2023

Health Outcomes and Cost-effectiveness of Monoclonal SARS-CoV-2 Antibodies as Pre-exposure Prophylaxis.

Stephanie Popping et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.